Literature DB >> 16959344

Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer.

Michele Stasi1, Fernando Munoz, Claudio Fiorino, Massimo Pasquino, Barbara Baiotto, Piergiorgio Marini, Giuseppe Malinverni, Riccardo Valdagni, Pietro Gabriele.   

Abstract

PURPOSE: To investigate the impact of rectum motion on dose - volume histograms of the rectum including filling and of the wall (DVH and DWH, respectively), during 3D-conformal radiotherapy (3DCRT) for localized prostate cancer.
MATERIALS AND METHODS: Ten patients received a planning CT scan (CT(0)) and 11-14 CT during 3DCRT for prostate cancer (total CT scans=126). CT images were 3D matched using bony anatomy. A single observer drew the external contours of rectum and rectum wall and the CTV (prostate + seminal vesicles) on CT(0). Patients were asked to empty their rectum before every CT, as generally performed at the Institute for Cancer Research and Treatment (IRCC) before treatment delivery. Bladder was kept full by drinking 500 cm(3) of water 60 min before the scan, according to our protocol. A 4-field box 3DCRT technique was planned and dose statistics/dose - volume histograms of the rectum were calculated for each contour referred to CT(0),CT(1),...,CT(n) for each patient. Average DVHs during treatment were calculated along with their standard deviation (SD(rand)) and compared to the planned DVH. The analyses on the patient population included the assessment of systematic deviation (average difference and SD, named SD(sys)) as well as the average SD(rand) value expressing the random component of organ motion. Rectum shifts were also assessed by anterior and lateral BEV projections.
RESULTS: As to the rectum, 8/10 patients showed a "better" average DVH than DVH on CT(0). Wilcoxon test showed a statistically significant reduction when correlating the difference Delta between the average DVH during therapy and planning DVH at CT(0): for instance V(70)Delta = -3.6% and p = 0.022, V(50)Delta = -5.5% and p = 0.022, D(med)Delta = -3.2 Gy and p = 0.007. Average values of DVH systematic difference (average difference between planning scan and treatment), standard deviations (SD(sys)) and average standard deviations of the random fluctuation (SD(random)) were -4.0%, 4.7% and 6.6%, respectively. Whilst the fluctuation results were slightly smaller for DWH. Volume analysis showed a slight systematic variation of the rectal volume between planning and treatment BEV. The average rectal volume during therapy was larger than at the planning CT in 8/10 patients. The systematic shifts of the rectal wall between the planning phase and the treatment were rather small, both below and above the flexure. The larger random fluctuation of the rectum shape was found to be in the cranial half (1 SD=4.4 mm).
CONCLUSIONS: The practice of carefully emptying the rectum during simulation and therapy for prostate cancer, which is a safe and simple procedure, reduces the impact of organ motion on dose - volume parameters of the rectum.

Entities:  

Mesh:

Year:  2006        PMID: 16959344     DOI: 10.1016/j.radonc.2006.08.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  24 in total

1.  Which bowel preparation is best? Comparison of a high-fibre diet leaflet, daily microenema and no preparation in prostate cancer patients treated with radical radiotherapy to assess the effect on planned target volume shifts due to rectal distension.

Authors:  S Yahya; A Zarkar; E Southgate; P Nightingale; G Webster
Journal:  Br J Radiol       Date:  2013-08-30       Impact factor: 3.039

2.  The impact of androgen deprivation therapy on setup errors during external beam radiation therapy for prostate cancer.

Authors:  Cem Onal; Yemliha Dolek; Yurday Ozdemir
Journal:  Strahlenther Onkol       Date:  2017-04-13       Impact factor: 3.621

3.  Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction.

Authors:  I F Maund; R J Benson; J Fairfoul; J Cook; R Huddart; A Poynter
Journal:  Br J Radiol       Date:  2014-10-29       Impact factor: 3.039

4.  Prostate image-guided radiotherapy by megavolt cone-beam CT.

Authors:  Sergio Zucca; Barbara Carau; Ignazio Solla; Elisabetta Garibaldi; Paolo Farace; Giancarlo Lay; Gianfranco Meleddu; Pietro Gabriele
Journal:  Strahlenther Onkol       Date:  2011-07-22       Impact factor: 3.621

5.  Variability in bladder volumes of full bladders in definitive radiotherapy for cases of localized prostate cancer.

Authors:  Naoki Nakamura; Naoto Shikama; Osamu Takahashi; Makiko Ito; Masatoshi Hashimoto; Masahiro Uematsu; Yukihiro Hama; Kenji Sekiguchi; Keiichi Nakagawa
Journal:  Strahlenther Onkol       Date:  2010-11-08       Impact factor: 3.621

6.  Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications.

Authors:  Leire Arbea; Luis Isaac Ramos; Rafael Martínez-Monge; Marta Moreno; Javier Aristu
Journal:  Radiat Oncol       Date:  2010-02-26       Impact factor: 3.481

Review 7.  [Radiotherapy for prostate cancer].

Authors:  Christian Stanek
Journal:  Wien Med Wochenschr       Date:  2007

8.  Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer?

Authors:  Adam D Melancon; Jennifer C O'Daniel; Lifei Zhang; Rajat J Kudchadker; Deborah A Kuban; Andrew K Lee; Rex M Cheung; Renaud de Crevoisier; Susan L Tucker; Wayne D Newhauser; Radhe Mohan; Lei Dong
Journal:  Radiother Oncol       Date:  2007-09-24       Impact factor: 6.280

9.  Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy.

Authors:  V Macias; R Gonzalez Celador; C Marti-Macia; C Cigarral; L A Perez-Romasanta
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

10.  Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer.

Authors:  John M David; Gillian Gresham; Salma K Jabbour; Matthew Deek; Shant Thomassian; John M Robertson; Neil B Newman; Joseph M Herman; Arsen Osipov; Peyman Kabolizadeh; Richard Tuli
Journal:  J Gastrointest Oncol       Date:  2018-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.